DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
NY-ESO-1-specific TCR-engineered T-cell Immunotherapy for Triple Negative Breast Cancer
[Technical Report, Annual Report]
METHODIST HOSPITAL HOUSTON TX
Pagination or Media Count:
Triple negative breast cancer TNBC is the most aggressive and difficultly treated subtype of metastatic breast cancer, with very limited treatment option due to lack of expression of estrogen receptors ERs, progesterone receptors PRs, or human epidermal growth factor receptor 2 HER2. Cancer immunotherapy is becoming a promising approach for cancer treatment with little or controllable side effect. We hypothesize that treatment of TNBC patients with NY-ESO-1 TCR-transduced T cells is safe and will result in tumor regression and clinical benefits.
[A, Approved For Public Release]